CAPR CAPRICOR THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1133869 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.5%
TTM net income YoY-81.6%
TTM EPS YoY-38.6%
Revenue 3-yr CAGR349.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-191.1%
Net margin-181.7%
FCF margin-184.8%
EBITDA margin-184.7%
Returns
ROE-48.2%
ROA-35.3%
ROIC (approx.)-47.3%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets14.7%
Debt / equity0.00x
Current ratio7.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $22.27M | $25.18M | $2.55M | $244,898 |
| R&D expense | $84.45M | $49.97M | $36.45M | $21.82M | $13.57M |
| SG&A expense | $23.69M | $14.87M | $12.81M | $10.43M | $7.61M |
| Operating income | -$108.14M | -$42.56M | -$24.08M | -$29.70M | -$20.94M |
| Interest expense | $3.05M | $0 | — | — | — |
| Pretax income | -$105.04M | -$40.47M | — | — | — |
| Income tax | $1,600 | $1,600 | — | — | — |
| Net income | -$105.04M | -$40.47M | -$22.29M | -$29.02M | -$20.02M |
| EBITDA | -$106.25M | -$41.14M | -$23.01M | -$29.16M | -$20.69M |
| EPS (basic) | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 |
| EPS (diluted) | -2.26 | -1.15 | -0.83 | -1.18 | -0.87 |
| Weighted avg. shares (diluted) | 46.48M | 35.22M | 26.78M | 24.55M | 23.09M |
| Balance sheet | |||||
| Cash & equivalents | $287.85M | $11.29M | $14.69M | $9.60M | $34.89M |
| Short-term investments | $30.28M | $140.23M | $24.79M | $31.82M | $0 |
| Current assets | $322.94M | $163.39M | $50.86M | $42.89M | $36.44M |
| PP&E, net | $18.31M | $5.56M | $5.56M | $4.59M | $1.80M |
| Intangibles | — | — | — | — | $0 |
| Total assets | $355.95M | $170.48M | $58.73M | $50.09M | $41.33M |
| Current liabilities | $35.84M | $21.03M | $31.27M | $23.59M | $4.13M |
| Total liabilities | $50.16M | $25.02M | $36.13M | $38.31M | $9.96M |
| Shareholders' equity | $305.79M | $145.46M | $22.60M | $11.79M | $31.37M |
| Shares outstanding | 57.37M | 45.58M | 31.15M | 25.24M | 24.19M |
| Cash flow statement | |||||
| Operating cash flow | -$69.81M | -$40.00M | -$25.60M | $4.92M | -$16.81M |
| Capital expenditure | $2.90M | $1.17M | $1.31M | $2.00M | $1.20M |
| Free cash flow | -$72.72M | -$41.16M | -$26.91M | $2.92M | -$18.01M |
| Investing cash flow | $97.48M | -$116.18M | $5.11M | -$35.07M | -$1.20M |
| Financing cash flow | $248.89M | $152.77M | $25.58M | $4.87M | $20.23M |
| Depreciation & amortization | $1.89M | $1.43M | $1.07M | $533,131 | $245,697 |
| Stock-based compensation | $17.23M | $9.77M | $7.39M | $4.46M | $2.97M |
Free plan shows the latest 5 periods; Pro shows all 20 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.